Business
Tiziana Advances Phase 2 Site Selection for Its Lead Clinical Program in Non-Active Secondary Progressive Multiple Sclerosis (SPMS) and The Company Prepares for Six-Month Clinical Data Update
--News Direct--By Rachael Green, BenzingaTiziana Life Sciences Ltd. (NASDAQ: TLSA) recently announced the Company has initiated site selection for its lead
About this update from Tiziana Life Sciences Ltd
[{"type":"text","content":"--News Direct--By Rachael Green, BenzingaTiziana Life Sciences Ltd. (NASDAQ: TLSA) recently announced the Company has initiated site selection for its lead intranasal anti-CD3 monoclonal antibody drug candidate “foralumab” program entering Phase 2a clinical testing in non-active Secondary Progressive Multiple Sclerosis (na-SPMS) patients. In total, the multi-center clinical trial will have six to ten new clinical trial sites across the US. According to the Company, another key data milestone is expected soon at the ECTRIMS conference, which will detail the results from the expanded access program after six months of treatment. Investors should take note, as this is a significant event for the company through providing six-month clinical results on the second cohort of four patients (numbers 3-6), and also providing a PET scan which shows neuroinflammation in the brain (microglia). ECTRIMS is the world’s largest research meeting in multiple sclerosis and will be held October 11-13 in Milan, Italy. Tiziana also recently announced the acceptance of a publication in the prestigious journal Proceedings of the National Academy of Sciences (PNAS) of its study validating the mechanism of action (MoA) using intranasally administered foralumab in Alzheimer’s disease (AD). The published study concluded that “nasal anti-CD3 has the potential to be a non-toxic novel immunotherapeutic approach for the treatment of Alzheimer’s disease (AD)”, which further supports the Company’s hypothesis for the use of foralumab in neurodegenerative disease. Key highlights from the Journal included: The authors conclude that “nasal anti-CD3 has the potential to be a non-toxic novel immunotherapeutic approach for the treatment of Alzheimer’s disease (AD)”FDA has cleared the IND for intranasal foralumab, a fully human anti-CD3 monoclonal antibody, for human study in mild to moderate Alzheimer’s DiseaseThe publication shows anti-CD3 monoclonal antibody (mAb) administered intranasally, ameliorates disease in a 3xTg model of Alzheimer’s disease by targeting microglial activation in the brain, while expanding regulatory T cells in the peripheryRemarkably, this reduced microglial activation and improved cognition occurs independent of amyloid beta disposition.The full publication can be found HERE Tiziana’s Foralumab Is A Promising Treatment With Potential To Treat ...